Placebo News and Research

RSS

Investigational drug targeting the opioid system may help reduce symptoms of major depression

Two clinical trials of an investigational drug that targets the opioid system support its safety and effectiveness in reducing symptoms of major depression, when added to standard antidepressant treatment.

29 Oct 2018

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

TherapeuticsMD, Inc., an innovative women's healthcare company, today announced that the United States Food and Drug Administration has approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

29 Oct 2018

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.

29 Oct 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

High-impact clinical trial results could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2018 October 23-October 28 at the San Diego Convention Center.

26 Oct 2018

Quadrant Biosciences announces collaboration on research into treatment of ASD

Quadrant Biosciences, Inc., an emerging life science company based in Syracuse, N.Y., today announced its collaboration with the Autism Speaks® Autism Treatment Network and its university research partners on research into the treatment of autism spectrum disorder.

26 Oct 2018

New flu drug Xofluza approved - FDA emphasizes importance of flu shots

A new drug that works against flu has been developed and has been approved by the Food and Drug Administration (FDA) yesterday (24th October 2018). Until now the only drug available for flu is oseltamivir (Tamiflu) which is to be administered by two pills per day for five days after symptoms appear.

25 Oct 2018

FDA approves new antiviral flu treatment

Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

24 Oct 2018

Novel drug extends survival for women with HR-positive metastatic breast cancer

The drug palbociclib, used in combination with standard treatment, improved survival for women with hormone receptor-positive metastatic breast cancer, according to a large phase III clinical trial.

24 Oct 2018

Cannabis oil shown to significantly improve Crohn’s disease symptoms

In the first study of its kind, cannabis oil has been shown to significantly improve the symptoms of Crohn’s disease and the quality of life of sufferers but, contrary to previous medical thinking, has no effect on gut inflammation.

23 Oct 2018

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Patients with an aggressive form of advanced breast cancer can benefit from immunotherapy when used in combination with chemotherapy as first-line treatment, according to the results of a large international Phase III clinical trial published today in the New England Journal of Medicine and led by a researcher at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine.

23 Oct 2018

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Treatment with the cyclin dependent kinase 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive human epidermal growth factor receptor-2 negative advanced breast cancer that has relapsed or progressed on hormonal therapy, according to the final analysis of overall survival results from the PALOMA-3 study reported at ESMO 2018.

23 Oct 2018

Drugs approved for breast cancer treatment are effective and well tolerated in men

There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies to be reported at ESMO 2018.

23 Oct 2018

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

Novartis announced today that the full data from the LIBERTY study of Aimovig (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet.

23 Oct 2018

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

$Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer$

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy.

22 Oct 2018

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation, results from the phase 3 SOLO-1 trial show.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

Placebo News and Research

Investigational drug targeting the opioid system may help reduce symptoms of major depression

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

High-impact clinical trial results could affect kidney-related medical care

Quadrant Biosciences announces collaboration on research into treatment of ASD

New flu drug Xofluza approved - FDA emphasizes importance of flu shots

FDA approves new antiviral flu treatment

Novel drug extends survival for women with HR-positive metastatic breast cancer

Cannabis oil shown to significantly improve Crohn’s disease symptoms

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Drugs approved for breast cancer treatment are effective and well tolerated in men

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Study: Targeting specific genomic mutation in breast cancer improves survival

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News